Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Similar articles for PubMed (Select 24298985)

1.

Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.

Verkaik NJ, Hoek RA, van Bergeijk H, van Hal PT, Schipper ME, Pas SD, Beersma MF, Boucher CA, Jedema I, Falkenburg F, Hoogsteden HC, van den Blink B, Murk JL.

Transpl Infect Dis. 2013 Dec;15(6):E243-9. doi: 10.1111/tid.12156. Epub 2013 Oct 23. Review.

PMID:
24298985
2.

Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.

Ciszek M, Mucha K, Foroncewicz B, Chmura A, Pączek L.

Ann Transplant. 2014 Jan 30;19:60-3. doi: 10.12659/AOT.884035.

3.
4.

A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.

Reddy AJ, Zaas AK, Hanson KE, Palmer SM.

J Heart Lung Transplant. 2007 Dec;26(12):1286-92. Epub 2007 Nov 19.

PMID:
18096480
5.

Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.

Avery RK, Bolwell BJ, Yen-Lieberman B, Lurain N, Waldman WJ, Longworth DL, Taege AJ, Mossad SB, Kohn D, Long JR, Curtis J, Kalaycio M, Pohlman B, Williams JW.

Bone Marrow Transplant. 2004 Dec;34(12):1071-5.

PMID:
15489872
6.

Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.

Minces LR, Nguyen MH, Mitsani D, Shields RK, Kwak EJ, Silveira FP, Abdel-Massih R, Pilewski JM, Crespo MM, Bermudez C, Bhama JK, Toyoda Y, Clancy CJ.

Antimicrob Agents Chemother. 2014;58(1):128-35. doi: 10.1128/AAC.00561-13. Epub 2013 Oct 21.

7.

Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.

Battiwalla M, Paplham P, Almyroudis NG, McCarthy A, Abdelhalim A, Elefante A, Smith P, Becker J, McCarthy PL, Segal BH.

Transpl Infect Dis. 2007 Mar;9(1):28-32.

PMID:
17313468
8.

Utility of leflunomide in the treatment of complex cytomegalovirus syndromes.

Avery RK, Mossad SB, Poggio E, Lard M, Budev M, Bolwell B, Waldman WJ, Braun W, Mawhorter SD, Fatica R, Krishnamurthi V, Young JB, Shrestha R, Stephany B, Lurain N, Yen-Lieberman B.

Transplantation. 2010 Aug 27;90(4):419-26. doi: 10.1097/TP.0b013e3181e94106.

PMID:
20683281
9.

New developments in the management of cytomegalovirus infection after solid organ transplantation.

Eid AJ, Razonable RR.

Drugs. 2010 May 28;70(8):965-81. doi: 10.2165/10898540-000000000-00000. Review.

PMID:
20481654
10.

Early onset of ganciclovir-resistant cytomegalovirus infection in a lung-transplant recipient.

Chen F, Bando T, Hanaoka N, Fukuse T, Hasegawa S, Wada H.

Jpn J Thorac Cardiovasc Surg. 2005 Oct;53(10):562-4.

PMID:
16279588
11.

Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide.

Waldman WJ, Knight DA, Lurain NS, Miller DM, Sedmak DD, Williams JW, Chong AS.

Transplantation. 1999 Sep 27;68(6):814-25.

PMID:
10515382
12.

Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus.

Germi R, Mariette C, Alain S, Lupo J, Thiebaut A, Brion JP, Epaulard O, Saint Raymond C, Malvezzi P, Morand P.

Antiviral Res. 2014 Jan;101:57-61. doi: 10.1016/j.antiviral.2013.10.014. Epub 2013 Nov 1.

PMID:
24184983
13.

Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.

Rodriguez J, Casper K, Smallwood G, Stieber A, Fasola C, Lehneman J, Heffron T.

Liver Transpl. 2007 Oct;13(10):1396-400.

14.

Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.

Mylonakis E, Kallas WM, Fishman JA.

Clin Infect Dis. 2002 May 15;34(10):1337-41. Epub 2002 Apr 10. Erratum in: Clin Infect Dis. 2006 May 1;42(9):1350.

15.

Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.

Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A, Hartmann A.

Transplantation. 2011 Jul 27;92(2):217-23. doi: 10.1097/TP.0b013e31821fad25.

PMID:
21685829
16.

Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients.

Gagermeier JP, Rusinak JD, Lurain NS, Alex CG, Dilling DF, Wigfield CH, Love RB.

Transpl Infect Dis. 2014 Dec;16(6):941-50. doi: 10.1111/tid.12317. Epub 2014 Dec 10.

PMID:
25491023
17.
18.

Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation.

West P, Schmiedeskamp M, Neeley H, Oberholzer J, Benedetti E, Kaplan B.

Transpl Infect Dis. 2008 Apr;10(2):129-32. Epub 2007 Jul 1.

PMID:
17605740
19.

Repopulation of ganciclovir-resistant cytomegalovirus by wild-type virus.

Drew WL, Liu C.

Clin Transplant. 2012 Nov-Dec;26(6):949-52. doi: 10.1111/j.1399-0012.2012.01681.x. Epub 2012 Jul 9.

PMID:
22774759
20.

Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients.

Bhorade SM, Lurain NS, Jordan A, Leischner J, Villanueva J, Durazo R, Creech S, Vigneswaran WT, Garrity ER.

J Heart Lung Transplant. 2002 Dec;21(12):1274-82.

PMID:
12490272
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk